Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HyPlex

Financiado

Cerrado

Hybrid polymer nanoparticles as gene vectors

Gene therapy has long been seen as a promising solution to unmet clinical needs and the licencing of gene therapy SARS-CoV-2 vaccines has provided a flavour of the technology’s potential. However, gene therapy still faces signifi... ver más

30/06/2026

ROYAL COLLEGE OF S...

216K€

Presupuesto del proyecto: 216K€

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-03

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ROYAL COLLEGE OF SURGEONS IN...

215.53K€ | Lider

Proyectos interesantes

PTQ-16-08701

Medical Technol...

Nanotechnology

62K€ Cerrado

RTI2018-097609-B-C22

Medical Technol...

Nanotechnology

57K€ Cerrado

PID2020-114356RB-I00

Medical Technol...

Nanotechnology

213K€ Cerrado

TraffikGene-Tx

Medical Technol...

Nanotechnology

2M€ Cerrado

NATPRIME

Nanotechnology

Medical Technol...

Cerrado

NanoDeliveryEnhance

Medical Technol...

Nanotechnology

150K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 38 meses Fecha Inicio: 2023-04-03
Fecha Fin: 2026-06-30

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 216K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Gene therapy has long been seen as a promising solution to unmet clinical needs and the licencing of gene therapy SARS-CoV-2 vaccines has provided a flavour of the technology’s potential. However, gene therapy still faces significant challenges in clinical and commercial translation including the need for effective and safe delivery vectors. Polymeric nanoparticles offer great flexibility in gene vectors design, improved stability and easier scale-up of production compared to lipid nanoparticles but often suffer from cytotoxicity and underperformance in vivo. The goal of HyPlex is to develop the next generation polymeric nanovectors which can easily be functionalised to further improve delivery efficacy. The project will develop novel chemistry to achieve polylysine/polyacrylate hybrid nanogels. Functionalisation of nanogels will be demonstrated by the introduction of mannose, a common cell binding motive as well as diethylene glycol ethyl ether arylate to optimise the hydrophilic/hydrophobic balance. In an interdisciplinary approach gene loading and cell transfection will be studied up to in vitro level. The project results will be exploited as part of an ongoing commercialisation initiative at RCSI, which will provide the applicant with a unique experience in research translation and commercialisation. The high-level science is complemented by bespoke training activities, which will significantly advance the career opportunities of the applicant. Project results will be communicated to peers as well as the public with specific focus on encouraging female secondary school pupils to take up scientific careers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores